CDK1 and glioblastoma: Finally, our pre-clinical study demonstrates that combination therapy with the Pin1 inhibitor sulfopin and the CDK1 inhibitor RO3306 most effectively suppresses SUMO1-modified sumoylation, inhibits GSC maintenance, and mitigates intracranial GBM growth.